Treatment for Non-Restorative Sleep After CBT-I Failure

Understanding the Clinical Picture

The American Academy of Sleep Medicine recommends targeting CNS hyperarousal mechanisms rather than providing simple sedation for patients with non-restorative sleep, morning fatigue, head tension, and muscle tension who have not responded to CBT-I 1

The American Academy of Sleep Medicine specifically recommends low-dose doxepin (3-6 mg at bedtime) as first-line pharmacotherapy for patients with persistent CNS hyperarousal despite adequate CBT-I, as it targets histamine H1 receptors to reduce arousal without the anticholinergic burden of higher doses 1
Low-dose pregabalin (75-150 mg at bedtime) is another evidence-based option that targets hyperarousal mechanisms rather than providing sedation, and may be particularly useful if muscle tension is a prominent feature 1
Ramelteon 8 mg works through melatonin receptor agonism to normalize circadian arousal patterns without sedation, and is particularly useful when hyperarousal has a circadian dysregulation component 1

The American College of Physicians recommends using a shared decision-making approach to add pharmacological therapy in adults with chronic insomnia disorder in whom CBT-I alone was unsuccessful, with eszopiclone and zolpidem improving global outcomes in the general population (low-quality evidence) 2, 3
Suvorexant (orexin antagonist) improved treatment response and sleep outcomes in mixed populations (moderate-quality evidence) 2, 3
Doxepin improved sleep outcomes with moderate to low-quality evidence 2, 3

Verify CBT-I adequacy by ensuring the patient received proper multicomponent CBT-I including sleep restriction, stimulus control, cognitive therapy, and sleep hygiene education over 4-8 sessions 4, 5
Rule out occult comorbidities by screening for sleep-disordered breathing, restless legs syndrome, or other medical conditions that could explain non-restorative sleep 6
Initiate low-dose doxepin (3-6 mg) or pregabalin (75-150 mg) at bedtime, and titrate after 1 week based on response and tolerability 1
Reassess at 4 weeks, and consider switching to ramelteon or combining low-dose doxepin with ramelteon if inadequate response 1

Track sleep diary data throughout treatment to objectively track changes 1
Monitor daytime arousal symptoms, including the "tight head" sensation and muscle tension 1
Monitor side effects, particularly daytime sedation, dizziness (with pregabalin), or anticholinergic effects (with doxepin, though minimal at low doses) 1
Reassess every 2-4 weeks initially, then every 6 months for long-term management 1